Drug Update logo on top of pills (green)

Drug Update: April 2018

Specialty Drug Approval New Biologic Drug Approved for Psoriasis: Ilumya® (tildrakizumab-asmn) In March 2018, the U.S. Food and Drug Administration (FDA) approved Ilumya® (tildrakizumab-asmn) for the treatment of adults with moderate to severe plaque psoriasis. It is indicated specifically for patients who are candidates for systemic therapy or phototherapy and is given as a subcutaneous […]

Drug Update logo on top of pills (orange)

Drug Update: March 2018

Specialty Drug Approvals New Drug Approved for Prostate Cancer: Erleada® (apalutamide) In February 2018, the U.S. Food and Drug Administration (FDA) approved Erleada® (apalutamide) for the treatment of patients with prostate cancer that has not spread to other areas (non-metastatic) and does not respond to other therapies used to lower testosterone (castration-resistant). Approval marks the […]

Drug Update logo on top of pills (purple)

Drug Update: February 2018

New Drug Approvals Firvanq® (vancomycin HCl) Approved for Infectious Diarrhea Firvanq® (vancomycin hydrochloride) oral solution received U.S. Food and Drug Administration (FDA) approval in January 2018 for the treatment of Clostridium difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains). Firvanq is the first and only FDA-approved vancomycin oral liquid indicated for C. […]

Drug Update logo on top of pills (gold)

Drug Update: January 2018

Specialty Drug Approvals Fasenra® (benralizumab) Approved to Treat Severe Eosinophilic Asthma In November 2017, AstraZeneca announced Fasenra® (benralizumab) had received FDA-approval as an add-on maintenance treatment for severe eosinophilic asthma in patients who are 12 years of age and older. Eosinophils are a type of white blood cell that can be elevated in patients with […]

Drug Update logo on top of pills (green)

Drug Update: December 2017

Specialty Drug Approvals New Gene Therapy Approved for Rare Vision-Threatening Condition: Luxturna® In December 2017, the U.S. Food and Drug Administration (FDA) approved the first gene therapy for treating patients with disease caused by a specific genetic mutation. Luxturna® (voretigene neparvovec-rzyl) is approved to treat children and adults with a rare, inherited condition causing loss […]

Drug Update logo on top of pills (orange)

Drug Update: November 2017

Vaccine Update New Shingles Vaccine, Shingrix®, Recommended Over Zostavax® Shingles occurs when the varicella zoster virus (VZV) is reactivated in a patient previously infected with the VZV virus. The VZV virus is responsible for causing the childhood illness chickenpox, and nearly all older adults already have the virus in their body. As an individual ages […]

Drug Update logo on top of pills (purple)

Drug Update: October 2017

New Specialty Drug Approvals New Treatment Approved for Metastatic Breast Cancer: Verzenio® On September 28, 2017, the U.S. Food and Drug Administration (FDA) approved Verzenio® (abemaciclib) for the targeted treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer that progressed after taking hormone altering […]

Drug Update logo on top of pills (gold)

Drug Update: September 2017

New Specialty Drug Approval FDA Approves First Gene Therapy: Kymriah® On August 30th 2017, the U.S. Food and Drug Administration (FDA) approved the first gene therapy for use in the United States. Kymriah® (tisagenlecleucel) is a cell-based gene therapy approved for the treatment of patients up to 25 years of age with refractory or relapsed (second or […]